Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
about
The β-Lactams Strike Back: Ceftazidime-AvibactamResponses of Pseudomonas aeruginosa to antimicrobialsIdentification of novel genes responsible for overexpression of ampC in Pseudomonas aeruginosa PAO1Changes in gram negative microorganisms' resistance pattern during 4 years period in a referral teaching hospital; a surveillance studyStructure and function of OprD protein in Pseudomonas aeruginosa: from antibiotic resistance to novel therapies.Side effects of antibiotics on genetic variability.Doripenem: position in clinical practice.Combination antibiotic therapy for empiric and definitive treatment of gram-negative infections: insights from the Society of Infectious Diseases Pharmacists.In vitro activity studies of doripenem and two other carbapenems tested against Pseudomonas aeruginosa and other non-fermentative bacilli.Shortening the course of antibiotic treatment in the intensive care unit.Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.The Impact of Antibiotic Stewardship Programs in Combating Quinolone Resistance: A Systematic Review and Recommendations for More Efficient Interventions.Mutational Consequences of Ciprofloxacin in Escherichia coliThe multifaceted roles of antibiotics and antibiotic resistance in nature.Selection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpC.Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.Risk Factors for Carbapenem-resistant Klebsiella pneumoniae Infection and Mortality of Klebsiella pneumoniae Infection.Clinical efficacy of i.v. doripenem, a new class of carbapenem, in patients with biliary tract infection: A multicenter trial.
P2860
Q26796425-9FB049F0-FD36-480D-8B7B-9B9EB4A7545BQ28305587-BF6A1921-B09A-4DAD-B8D2-CBBF4ACDFBCCQ28492757-481B6362-E996-41A7-92DE-7C02BC5D760CQ36564502-B38FE3FB-BA06-4438-99D7-34DA149C15C9Q37317645-9F7D3ABC-EA5D-43A4-8082-36DA8EE56D04Q37406333-75688245-F82C-43D0-A7DC-0CFD51DD1D62Q37503320-0D1DDA87-FEF5-44A5-A749-5EC689853522Q37949391-69C2A6BB-9B09-4646-9484-E29C1766565EQ37974745-8D30C4EA-A51F-49F2-9E00-11C42570F541Q38341882-AFB880D0-CB19-4D54-9FBB-A7B4E27701E8Q38844899-A612428B-FE21-473C-AD37-437F3EEA9967Q39183151-BD7B495F-E5DD-43FD-B75A-5D359BAF783AQ41194789-4EAD3238-1FDA-49FF-AF83-C1106F309F8BQ41249257-F6D5C94D-98D6-43C2-ADA8-F93F378A58ABQ41508049-10117CFA-DA85-4CD9-BF31-72D7BE0A01F1Q44001871-76C1DB36-A84F-49DF-804D-EDF55C8F145FQ47260522-2EC43540-B9E4-4865-B3C5-4944C425351DQ50178436-CCAFB76E-3506-4FBC-B42D-021FE0963987
P2860
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Fluoroquinolone enhances the m ...... nem inhibits mutant formation.
@en
Fluoroquinolone enhances the m ...... nem inhibits mutant formation.
@nl
type
label
Fluoroquinolone enhances the m ...... nem inhibits mutant formation.
@en
Fluoroquinolone enhances the m ...... nem inhibits mutant formation.
@nl
prefLabel
Fluoroquinolone enhances the m ...... nem inhibits mutant formation.
@en
Fluoroquinolone enhances the m ...... nem inhibits mutant formation.
@nl
P2093
P2860
P356
P1476
Fluoroquinolone enhances the m ...... nem inhibits mutant formation.
@en
P2093
Haruyoshi Tomita
Katsuko Okuzumi
Koichi Tanimoto
Shuhei Fujimoto
Yasuyoshi Ike
P2860
P304
P356
10.1128/AAC.00464-08
P407
P577
2008-08-11T00:00:00Z